AGS-009 (Argos Therapeutics)

N/A

Report date: 2022/11/25 17:56:33

Base Information

Drug NameAGS-009 (Argos Therapeutics)
Drug Alias NameAGS-009NNC-015200000001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterferon alpha inhibitors
TargetsInterferon alpha
Therapy Area/IndicationsInflammationLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArgos Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArgos Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsInflammationLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A